Join
Live feed
·
NEWSReleasevia Quantisnow
Gracell Biotechnologies Inc. logo

Gracell Biotechnologies Announces FDA Clearance For Its Investigational New Drug Application For Phase 1 Trial Of GC012F In The U.S. For The Early-line Treatment Of Multiple Myeloma

ByQuantisnow·Wall Street's wire, on your screen.
GRCL· Gracell Biotechnologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GRCL (Gracell Biotechnologies Inc.) and more on Quantisnow.